Navigation Links
Digital Assent Secures $2 Million Series A Financing to Grow PatientPad Point-of-Care Network
Date:1/24/2011

solutions.

"This is an experienced team with the expertise and energy to fill a large and growing need," said Sig Mosely, president of Imlay Investments, who has made investments in more than 120 start-ups and private companies over the last two decades and is recognized for his leadership in building and growing the Georgia technology community. "We see great potential here."

Along with Imlay, two other angel investors, James Balloun and David McKenney, are part of Digital Assent's first round of financing.  All three angels had a previous relationship with Ibbotson, having invested in his former company, Synthis Corporation, which had a successful exit prior to the creation of Digital Assent.

In addition to the angels, three new investors joined Digital Assent's initial round of financing.  Fulcrum Equity Partners, BLH Venture Partners, and Mark Buffington of Buckhead Investment Partners all contributed to close out the $2 million Series A financing.

"We expanded our round after hearing from these investors that they were interested in joining our angels," explained Ibbotson.  "We are proud to have raised capital that comes with proven strategic and operational guidance from these new partners, and we look forward to working with them to continue to grow our business."

Frank X. Dalton, general partner at Fulcrum Equity Partners added, "Ibbotson and his team did an excellent job of proving the demand for the PatientPad in 2010.  Not only does the PatientPad streamline the check-in process, it also provides pharmaceutical and health organizations a cost effective way to deliver targeted educational messaging directly to interested patients at the point-of-care.  We are pleased to be a part of this venture."

The $2 million financing has already allowed Digital Assent to make strides towards securing customers outside of the Southeast; in early January the team signed its first customers in New York,
'/>"/>

SOURCE Digital Assent
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
2. Verathon Introduces the GlideScope(R) Cobalt Advanced Video Laryngoscope (AVL); New Digital Technology Facilitates Quick Intubations
3. Escalon(R) Subsidiary Escalon Digital Solutions Announces Release of Web-Based AXIS(TM) Image Management System
4. Now Approved: Fujifilms FDR AcSelerate Direct Digital DR System
5. World Renowned Physician and Thought Leader Dr. Eric J. Topol to Highlight Digital Medicine Revolution at International CES 2010
6. Womens Digital Imaging Using DXA Total Body Fat Analysis to Help Patients in Weight Management and Fitness Programs
7. Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit
8. Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago
9. Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard
10. Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation
11. Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- The escalation ... proteins, is placing renewed emphasis on alternate delivery ... as a number of factors are converging to ... makers and their delivery device partners . These ... conditions, the growing trend toward self-administration for chronic ...
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
(Date:5/17/2013)... May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 ... in both dose groups. The primary endpoint assessed the ... Consistent with data reported in previous trials, the most ... Full results will be presented at an upcoming medical ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... April 17, 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. ... conducted Phase 2 clinical trials,of GVAX immunotherapy ... patients with advanced prostate cancer from these,studies ... responses to a broad array of prostate ...
... A 9-month, randomized,double-blind, parallel-group Phase II study of ... given daily to the currently,approved COPAXONE(R) 20 mg ... disease activity as measured by magnetic,resonance images (MRI) ... mg experienced a reduced mean on-trial relapse rate,of ...
Cached Medicine Technology:Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 2Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 3Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 2Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 3Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 5
(Date:5/19/2013)... (PRWEB) May 19, 2013 Passages Malibu, ... treatment center, has announced this week the launch of ... the brands’ social media channels. “We are always ... treatment community and to get feedback regarding sobriety, what’s ... CEO and co-founder of the Passages Addiction Treatment ...
(Date:5/19/2013)... 19, 2013 The AMTC team will be ... Columbus Georgia Convention & Trade Center on June 1st. Professionals ... AMTC auditions are free of charge. , Actors, Models and ... hundreds of successful artists and grads like Caitlin Kinney - ... Tombolini , Chris Young - on his Liquid Neon 2013 ...
(Date:5/19/2013)... May 19, 2013 The legal team ... YazSideEffects.com in a concerted effort to connect women and ... birth control drugs Yaz, Yasmin & Ocella with the ... of information on the notorious birth control drugs as ... Pharmaceuticals. , Yaz, Yasmin & Ocella were very ...
(Date:5/18/2013)... 19, 2013 In “Cooking with Spirits for ... , author Janet Hall Svisdahl’s new cookbook, readers are transported ... to make even the pickiest eater drool. “I dedicate this ... she explains. , Found within the 364 pages of ... of delicious recipes, from fast and simple to gourmet. Each ...
(Date:5/18/2013)... 19, 2013) Each year, the American Gastroenterological ... contributions and achievements in gastroenterology through its esteemed ... distinguished and talented individuals who work tirelessly to ... we are pleased to announce the 2013 recognition ... colleagues for their tremendous contributions to our field," ...
Breaking Medicine News(10 mins):Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:Actors, Models and Talent for Christ Hosting Auditions in Columbus, GA June 1st in Search of Local Talent 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 3Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 4Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 5
... , MOUNTAIN VIEW, CA (October 25, 2011) ... the first-time discovery of the potentially protective nature of ... to be protective against a high-risk leucine-rich repeat kinase ... The LRRK2 gene is recognized as a significant risk ...
... of blood proteins can predict which patients with the progressive ... at least five years or to die within two years, ... and Centocor R&D. The findings, published online last week in ... , could help doctors determine those patients in imminent ...
... TUESDAY, Oct. 25 (HealthDay News) -- Training parents in ... conduct of preschool children with symptoms of attention-deficit/hyperactivity disorder ... also found insufficient evidence to support the use of ... age, but two drugs are generally safe and effective ...
... -- Teens who don,t get enough sleep may find themselves putting ... for obesity, new research suggests. In the study, researchers surveyed ... and found that the average sleep time on weekdays was 6 ... females. The average sleep time on weekends was 9 hours 10 ...
... supplements eaten for four to six weeks prior to prostate ... -- the number of rapidly dividing cells -- in ... diet. Done by researchers at UCLA,s Jonsson Comprehensive Cancer ... the low-fat, fish oil supplement diet were able to change ...
... new study in the Journal of Bone and Joint ... lumbar disc symptoms were significantly worse if the patients had ... to those who had symptoms for six months or less. ... satisfaction. "Patients often ask their physicians whether ...
Cached Medicine News:Health News:23andMe discovers genetic variant that may protect those at risk for Parkinson's disease 2Health News:Blood proteins predict survival in idiopathic pulmonary fibrosis, Pitt-led team says 2Health News:Parental Training May Benefit ADHD Kids Under 6: Report 2Health News:Sleepy Teens More Prone to Weight Gain: Study 2Health News:You are what you eat: Low fat diet with fish oil slowed growth of human prostate cancer cells 2Health News:You are what you eat: Low fat diet with fish oil slowed growth of human prostate cancer cells 3Health News:You are what you eat: Low fat diet with fish oil slowed growth of human prostate cancer cells 4Health News:Surgical treatment within six months of lumbar disc herniation 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: